Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P78352

UPID:
DLG4_HUMAN

ALTERNATIVE NAMES:
Postsynaptic density protein 95; Synapse-associated protein 90

ALTERNATIVE UPACC:
P78352; B7Z1S1; G5E939; Q92941; Q9UKK8

BACKGROUND:
The protein Disks large homolog 4, known alternatively as Postsynaptic density protein 95 or Synapse-associated protein 90, plays a critical role in the formation and plasticity of synaptic connections. It ensures the postsynaptic clustering of key proteins, modulates the activity of NMDA receptors and potassium channels, and is essential for the synaptic plasticity associated with NMDA receptor signaling. Additionally, DLG4 is involved in the regulation of AMPA receptor activation and the intracellular trafficking of specific proteins.

THERAPEUTIC SIGNIFICANCE:
Mutations in DLG4 are associated with Intellectual developmental disorder, autosomal dominant 62, indicating its crucial role in intellectual development. The exploration of DLG4's functions offers promising avenues for developing targeted therapies for intellectual disabilities and synaptic dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.